Hospira's filgrastim biosimilar given CHMP nod
This article was originally published in Scrip
The EU's CHMP has adopted a positive opinion on Hospira's Nivestim (filgrastim; 12MU/0.2ml, 30MU/0.5mg, 48MU/0.5ml) solution for injection or infusion for the treatment of neutropenia. Nivestim is a biosimilar of Amgen's Neupogen which was the reference product for the application.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.